Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Gains from Investment Securities (2019 - 2025)

aTYR PHARMA (ATYR) has disclosed Gains from Investment Securities for 6 consecutive years, with -$400000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities fell 8.4% year-over-year to -$400000.0, compared with a TTM value of $31000.0 through Sep 2025, down 91.44%, and an annual FY2023 reading of $6000.0, down 93.48% over the prior year.
  • Gains from Investment Securities was -$400000.0 for Q4 2025 at aTYR PHARMA, down from $136000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $1.0 million in Q1 2023 and bottomed at -$1.0 million in Q2 2023.
  • Average Gains from Investment Securities over 4 years is $7000.0, with a median of $124000.0 recorded in 2024.
  • Peak annual rise in Gains from Investment Securities hit 111.94% in 2024, while the deepest fall reached 5171.43% in 2024.
  • Year by year, Gains from Investment Securities stood at -$708000.0 in 2022, then skyrocketed by 99.01% to -$7000.0 in 2023, then plummeted by 5171.43% to -$369000.0 in 2024, then fell by 8.4% to -$400000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for ATYR at -$400000.0 in Q4 2025, $136000.0 in Q3 2025, and $133000.0 in Q2 2025.